19th February 2015
article written by
Cell Medica

Cell Medica begins commercial production at newly licensed cell therapy manufacturing facility in Germany

Start of commercial cell therapy manufacturing at the Max-Delbrück-Center of Molecular Medicine in Berlin-Buch (Germany). London, UK – 19 February 2015 : Cell Medica, a leading cellular immunotherapy company, today announced the start of commercial cell therapy manufacturing at its facility at the Max-Delbrück-Center of Molecular Medicine in Berlin-Buch (Germany). The first product has been successfully […]

Read Full Article
25th November 2014
article written by
Cell Medica

Cell Medica announces £50 million Series B round to advance cancer program

Closing of a £50 million Series B investment round is announced with participation from Imperial Innovations, Invesco Perpetual and Woodford Investment Management. London, UK – 25 November 2014: Cell Medica, a leading cellular immunotherapy company, today announced the closing of a £50 million Series B investment round with participation from Imperial Innovations, Invesco Perpetual and Woodford […]

Read Full Article